peptidasa (DPPIV)

Peptidase (Proteolytic Enzyme): A Comprehensive Reference

1. Identity, Nomenclature, and Overview

Peptidase is the formal biochemical designation for any enzyme that catalyzes the hydrolysis — that is, the cleavage by water — of peptide bonds within proteins or peptide chains. The term is used interchangeably with protease and proteinase, and these enzymes are widely applied in the food industry (bakery, beverages, dairy, meat processing, dietary supplements) and in the pharmaceutical industry. Proteolytic enzymes are essential for many important processes in the body and are also called peptidases, proteases, or proteinases.

As a dietary supplement category, "peptidase" refers not to a single molecule but to a diverse group of protein-degrading enzymes — frequently sold alone or in combination — that originate from plant, animal, fungal, and microbial sources. Peptidase, also known as protease, refers to a group of enzymes that break down proteins into smaller peptides and amino acids; historically, peptidases have been sourced from various origins, including plants (such as papain from papaya and bromelain from pineapple), animals (like pancreatin), and microorganisms.

1.1 Biochemical Classification

The scientific classification of peptidases is maintained by the MEROPS database, a leading curated information resource for proteolytic enzymes, their substrates, and inhibitors. The MEROPS database is a manually curated information resource for peptidases (also known as proteases, proteinases, or proteolytic enzymes), their inhibitors and substrates. The organizational principle of the database is a hierarchical classification in which homologous sets of the proteins of interest are grouped in families, and the homologous families are grouped in clans.

As of March 2022, there were 281 protein families in the MEROPS peptidase database, comprising 4,431 peptidases with identifiers, classified into nine catalytic types: aspartic (A, 324), cysteine (C, 1,059), glutamic (G, 22), metallo (M, 1,098), asparagine (N, 24), mixed (P, 54), serine (S, 1,728), threonine (T, 105), and unknown/unclassifiable (U, 17).

At the higher taxonomic level of clans: clans are identified by two letters; the first letter relates to the catalytic mechanism: A (aspartic), C (cysteine), M (metallo), S (serine), T (threonine), G (glutamic), or U (unknown mechanism). In the MEROPS database, peptidases are classified by structural similarities in the parts of the molecules responsible for their enzymatic activity. They are grouped into families on the basis of amino acid sequence homology, and the families are assembled into clans in light of evidence that they share common ancestry.

The most commercially important peptidases found in dietary supplements are predominantly cysteine proteases (e.g., bromelain, papain) and serine proteases (e.g., serratiopeptidase, trypsin, chymotrypsin). Bromelain belongs to the peptidase family C1. Papain (EC 3.4.22.2) is a cysteine protease acquired from the latex of the papaya plant (Carica papaya).

1.2 Principal Enzymes in Supplement Form

Proteolytic enzymes that may be found in supplements include bromelain, chymotrypsin, ficin, papain, serrapeptase, and trypsin. Dipeptidyl peptidase IV (DPP-IV) is another specific peptidase type increasingly featured on supplement labels, particularly in formulas targeting gluten and casein digestion. Dipeptidyl peptidase-4 (DPP-IV, also called DPP-4 or CD26) is an enzyme the body makes that clips tiny pieces off certain peptides, including hormones that regulate blood sugar and many immune-signaling molecules.

Commercial proteolytic enzyme supplement products usually contain a mixture of pancreatin, papain, bromelain, trypsin, and chymotrypsin. A specialized sub-category of supplement peptidases are post-proline cleaving enzymes (PPCEs), including prolyl endopeptidase (PEP/POP), which are targeted at breaking proline-rich sequences found in gluten and certain other food proteins. Both PEP and POP hydrolyze polypeptides at the C-terminal of proline residues (Pro-Xaa), with PEP not restricted by protein size, while POP can only cleave small peptides.

2. Natural Sources

Peptidases with supplement applications are derived from several kingdoms of life:

• Pineapple (Ananas comosus): Bromelain is a mixture of proteolytic enzymes primarily extracted from the fruit and stem of the pineapple plant (Ananas comosus). Extracts of Ananas comosus stem contain at least eight different proteolytic enzymes.
• Papaya (Carica papaya): The papaya fruit (Carica papaya) contains several proteolytic enzymes (papain, chymopapain A, chymopapain B, and papaya peptidase A) and is mainly used in wound débridement.
• Animal sources: In the human body, proteolytic enzymes are produced by the pancreas and stomach. Animal-derived pancreatin — a mixture of pancreatic enzymes including trypsin and chymotrypsin — is extracted from porcine or bovine pancreas and used in pharmaceutical-grade formulations.
• Microbial sources: Serratiopeptidase (also known as serralysin, serratia-protease, or serrapeptase) is a proteolytic enzyme originally isolated from the gut bacterium Serratia marcescens, a microorganism found in the gut of the silkworm. The Aspergillus niger aspergilloglutamic peptidase (AGP), formerly called aspergillopepsin II, is isolated from Aspergillus niger.
• Fungal sources: Aspergillus-derived proteases are widely used in supplement formulations for DPP-IV activity. An Aspergillus protease with DPP-IV aminopeptidase activity is used in enzyme supplement products.

3. Common Forms and Preparations

Proteases are widely used in the food industry (bakery, beverages, dairy, meat processing, dietary supplements), pharmaceutical industry (thrombolytic production, digestive aid, debridement and wound healing), and cosmetics industry. In the supplement sector specifically, peptidases are prepared and sold in the following forms:

• Oral capsules and tablets: The most common delivery format. Enteric-coated formulations are often used to protect acid-labile enzymes from gastric degradation. Enteric coated oral formulations of serratiopeptidase are being used in various specialties for their anti-inflammatory and anti-edemic properties.
• Enzyme blends: Products usually contain a mixture of pancreatin, papain, bromelain, trypsin, and chymotrypsin. Specialty gluten-focused blends also include DPP-IV enzymes alongside other endopeptidases.
• Topical preparations: Certain peptidases such as papain and bromelain have been formulated into topical ointments and gels for wound debridement, though regulatory restrictions apply in some jurisdictions. The U.S. Food and Drug Administration (FDA) in 2008 ordered a halt to the marketing of unapproved drug products that contain papain in a topical dosage form, citing concerns over hypersensitivity resulting in anaphylactic reactions as the primary concern.
• Standardized enzyme activity units: The enzyme activity is measured in units; serratiopeptidase 10 mg is equal to 20,000 units of enzyme activity. Bromelain is typically measured in Gelatin Digesting Units (GDU) or Milk Clotting Units (MCU).

4. Traditional and Historical Use

The use of peptidase-rich natural materials predates the formal science of enzymology by centuries. Traditional uses were empirical, based on observations of the digestive and wound-healing properties of certain fruits and plant materials.

4.1 Indigenous and Pre-Modern Traditions

The history of bromelain dates back to the ancient civilizations of South America, where the pineapple plant (Ananas comosus) is native. Indigenous peoples in Central and South America, particularly in regions like the Amazon rainforest and the Caribbean, used various parts of the pineapple plant for medicinal purposes, including treating digestive issues, reducing inflammation, and healing wounds.

Ancient civilizations, such as those in China and India, utilized peptidase-rich preparations derived from papaya (papain) and pineapple (bromelain) as natural remedies to aid digestion, reduce inflammation, and treat wounds. These enzymes were often incorporated into poultices or consumed as part of herbal concoctions to address gastrointestinal discomfort, bloating, and other digestive ailments.

Papain derived from Carica papaya has a particularly well-documented traditional history. Papain was used to prevent burn infections, defibrinate wounds, treat insect bites, treat oedema and inflammatory processes, and promote wound healing, as well as — in low dosages — in the event of stomach upsets.

4.2 Integration in Traditional Medicine Systems

Throughout the ages, peptidases have also played a significant role in herbal combinations. In traditional medicine systems, they are frequently blended with other botanicals — such as ginger, licorice, and fennel — to create synergistic formulas aimed at enhancing digestive health and overall vitality.

4.3 Transition to Modern Medical Use

Bromelain was first isolated and described in the late 19th century by researchers in Europe, who identified its proteolytic properties. Since then, bromelain has gained recognition in both traditional and modern medicine for its potential therapeutic effects.

The use of enzymes like trypsin, chymotrypsin, and bromelain as anti-inflammatory agents came into practice after it was observed during the 1950s in the USA that parenteral trypsin could be used to relieve post-surgical inflammation and that due to traumatic injury caused by sports, as well as inflammation due to conditions like rheumatoid arthritis, ulcerative colitis, and atypical viral pneumonia.

Proteolytic enzyme treatments were first used in Germany in the 1960s for inflammation, osteoarthritis, autoimmune diseases, and viral infections. The products usually contain a mixture of pancreatin, papain, bromelain, trypsin, and chymotrypsin.

Serratiopeptidase, a proteolytic enzyme, has been used for almost 40 years in Japan and Europe for pain and inflammation.

5. Key Constituents and Active Compounds

When "peptidase" supplements are consumed, the key bioactive components are the enzyme proteins themselves. Their effects are primarily mediated through their catalytic proteolytic activity, though some ancillary compounds may also be present depending on the source extract.

5.1 Bromelain

Bromelain is a complex natural mixture of sulfhydryl-containing proteolytic enzymes that can be extracted from the stem or fruit of the pineapple. Bromelain is an enzyme mixture whose most important component is a proteolytic thiol fraction. Other components include a peroxidase, acid phosphatase, several protease inhibitors, and calcium.

5.2 Papain

Papain (EC 3.4.22.2) is a cysteine protease acquired from the latex of the papaya plant (Carica papaya). The enzyme has been reported to have a high optimal temperature (65°C) and a wide pH range (5–8) for its activity. Commercial use of enzymes from varied industries involves different ratios of papain, chymopapain, and papaya peptidase A, resulting in distinctive physical, chemical, and biological characteristics.

5.3 Serratiopeptidase

Serratiopeptidase (serralysin/serratia-protease/serrapeptidase) is a widely used proteolytic enzyme in therapeutic applications. It is a metalloprotease originally derived from the symbiotic bacterium Serratia marcescens found in the intestines of silkworms, and now produced commercially through microbial fermentation.

5.4 Trypsin and Chymotrypsin

Trypsin and chymotrypsin are serine proteases belonging to the S1 family. The three main proteolytic pancreatic enzymes are trypsin, chymotrypsin, and carboxypeptidase. These are typically derived from animal pancreas and used in systemic enzyme therapy formulations, often in combination with flavonoids such as rutoside.

5.5 Dipeptidyl Peptidase IV (DPP-IV)

DPP-IV works by cleaving peptide bonds between dipeptides or tripeptides, which are small chains of amino acids that make up larger protein molecules. Unlike other proteases, DPP-IV can break double bonds that are resistant to hydrolysis, making it particularly effective at breaking down certain types of resistant proteins.

5.6 Prolyl Endopeptidase (PEP)

Prolyl endopeptidase is a serine peptidase of the S9 family that cleaves specifically at the carboxyl side of proline residues. A prolyl endopeptidase (PEP) from Flavobacterium meningosepticum, at molar concentrations only one one-hundredth of those of the digestive-resistant 33-mer gliadin peptide, is capable of efficiently cleaving it to smaller peptides that are non-toxic and can be readily further digested and absorbed.

6. Established Mechanisms of Action

Peptidases are localized extracellularly or intracellularly in the cytoplasm, the nucleus, or packaged into lysosomal/endosomal vesicles. Peptidases have important physiological functions in a number of biological processes where they act either as degradative enzymes or as regulatory enzymes that alter peptide function after cleavage of one or more specific peptide bonds.

The proposed mechanisms of action of supplemental peptidases span several biological pathways:

• Luminal protein digestion: The body produces proteolytic enzymes to help break down dietary proteins like meat, eggs, and fish into smaller fragments called amino acids, which can then be properly absorbed and digested.
• Systemic absorption with retained activity: Some evidence suggests that undegraded protein can be detected in the plasma after oral intake. In a study of 19 volunteers, the permeability of the intestinal mucosa for large protein molecules was studied using bromelain as the model enzyme; small amounts of bromelain were detected in the plasma, with part of its enzymatic activity retained.
• Anti-inflammatory effects: The mechanism of action of OTC enzyme supplements is not entirely clear as there are a number of studies demonstrating both pro-inflammatory and anti-inflammatory effects. The proposed anti-inflammatory mechanism relates to the ability of proteolytic enzymes to degrade pro-inflammatory mediators and immune complexes. Preclinical studies indicate that PEs have immunomodulatory and tumoricidal properties. Such effects are thought to result from degradation of abnormal immune complexes.
• Anti-edemic mechanism: Proteolytic enzymes help break down plasma proteins and cellular debris at the site of an injury into smaller fragments. This greatly facilitates their passage through the lymphatic system, resulting in more rapid resolution of swelling, with the consequent relief of pain and discomfort.
• Fibrinolytic activity: Several peptidases exhibit fibrinolytic effects, breaking down fibrin clots and supporting normal vascular flow. This is a key rationale for their use in post-surgical and sports-injury contexts.
• Gluten/casein hydrolysis: The gastrointestinal proteases are unable to fully degrade proline-rich molecules, resulting in a number of gluten-related disorders including wheat allergy and celiac disease. Specific peptidases such as PEP and DPP-IV are designed to supplement this deficiency. Specific endo- and exopeptidases, such as prolyl endopeptidase (PEP) and dipeptidyl peptidase-IV (DPP-IV), have been shown to cleave terminal proline-containing dipeptides in vitro and may be helpful in reducing levels of bioactive prolyl peptides in the intestinal tract.
• DPP-IV metabolic signaling: Dipeptidyl-peptidase IV (DPP-IV) plays an essential role in glucose metabolism by inactivating incretins. In this context, food-protein-derived DPP-IV inhibitors are promising glycemic regulators which may act by preventing the onset of type 2 diabetes in personalized nutrition.
• Immune modulation via CD26: DPP-IV has been shown to be identical to CD26, a cell surface marker for activated immune cells. The expression of CD26 is regulated by the differentiation and activation status of immune cells.

7. Scientific Evidence by Area of Use

7.1 Digestive Health and Protein Digestion

The most obvious use of proteolytic enzymes is to assist digestion. Improving digestion is the most common reason individuals take supplemental proteolytic enzymes. While most people only need occasional support, those with cystic fibrosis, certain types of cancer (such as colon, pancreatic, or stomach cancer), inflammatory bowel disease, irritable bowel syndrome, pancreatic exocrine insufficiency, and those who have undergone gastrointestinal surgery often require therapeutic doses to replace missing enzymes.

One randomized double-blind clinical trial involving 40 patients suffering from digestive upset found that taking a proteolytic enzyme supplement eased digestive symptoms including abdominal pain, belching, bloating, heartburn, and loss of appetite.

However, not all controlled studies confirm broad digestive benefit. A small, double-blind, placebo-controlled trial found no benefit from proteolytic enzymes as a treatment for dyspepsia (indigestion). The overall clinical evidence for digestive support — outside of established enzyme replacement contexts such as pancreatic exocrine insufficiency — remains limited and somewhat mixed.

7.2 Celiac Disease and Gluten Sensitivity

DPP-IV is normally present in the intestinal brush border, but studies show its activity is abnormally low in children and adults with celiac disease, and persons with autism spectrum disorders actually produce anti-DPP-IV antibodies. These factors suggest supplemental peptidases may be of therapeutic value in managing disorders associated with reactivity to gluten and/or casein.

Commercial enzyme blends are available to aid in gluten degradation, but whether or not these enzyme blends are effective in degrading gluten is essentially unknown. A study found that commercial gluten-detoxifying enzyme supplements have lower proteolytic activity than the pure dipeptidyl peptidase DPP-IV enzyme, as the gastrointestinal proteases are unable to fully degrade proline-rich molecules.

In animal and in vitro research, PEP has demonstrated promise: experiments demonstrate that a prolyl endopeptidase (PEP) from Flavobacterium meningosepticum, at molar concentrations only one one-hundredth of those of the digestive-resistant 33-mer gliadin peptide, is capable of efficiently cleaving it to smaller peptides that are non-toxic and can be readily further digested and absorbed by the rat intestine. Studies have shown that different PEPs can cleave a 33-mer gliadin peptide from wheat and synthetic peptides at different rates for different species. Human clinical trial data in celiac disease specifically remain limited and preliminary; definitive RCT evidence is still lacking.

7.3 Inflammation and Post-Surgical Recovery

This is one of the most clinically investigated areas for supplemental peptidases. Proteolytic enzymes are known for their anti-inflammatory effects and digestive tolerance; they have shown efficacy in reducing postoperative edema and inflammation. First introduced intravenously in the 1950s, oral systemic enzyme therapy now presents a non-invasive approach to managing inflammatory symptoms post-surgery.

Animal studies have supported anti-inflammatory activity across multiple enzyme types: Chymotrypsin (5, 18, and 36 mg/kg), trypsin (1.44, 2.88, and 5.76 mg/kg), and serratiopeptidase (0.45, 0.9, and 2.70 mg/kg) showed dose-dependent anti-inflammatory activity in acute models. Serratiopeptidase showed better anti-inflammatory activity on carrageenan-induced inflammation than the other two proteolytic enzymes and aspirin. Chymotrypsin, trypsin, and serratiopeptidase possess anti-inflammatory activity and exhibit synergistic effect with aspirin in both acute and subacute models of inflammation in rats.

In human wound healing, a phase-IV randomized clinical trial of 200 patients after elective orthopedic surgery examined a fixed-dose combination of trypsin and bromelain. This study was designed to assess the safety and effectiveness of Tibrolin® (a fixed-dose combination of trypsin 48 mg, bromelain 90 mg, and rutoside 100 mg tablet) in improving wound healing and alleviating acute pain in patients following uncontaminated surgeries. A phase-IV, open-label, prospective, multi-center clinical study was conducted on 200 patients after elective, clean, uncontaminated surgery, enrolling patients of both sexes aged between 18 and 65 years. No adverse events were observed. Both groups demonstrated statistically significant improvement (p < 0.001) in all assessed wound symptoms: erythema, edema, discharge, induration, local irritation, tenderness, and pain.

In a dental surgery context, a randomized clinical trial compared the efficacy of a combination of bromelain, rutocide, and trypsin versus serratiopeptidase in reducing postoperative sequelae. Group A received trypsin 48 mg, bromelain 90 mg, rutoside 100 mg, and diclofenac 50 mg twice daily, and Group B received serratiopeptidase 15 mg twice daily for five days. Outcome parameters including pain (VAS) and mouth opening were measured on postoperative days one and seven.

Evidence strength: The evidence for post-surgical anti-inflammatory and anti-edemic effects is the most robust area for these enzymes, supported by multiple clinical trials. However, many studies use combination products (enzymes plus flavonoids), making it difficult to isolate the contribution of the peptidase component alone. Some studies suggest potential benefits for sports injuries and inflammation, but results have varied widely, with many studies lacking robust design or placebo controls.

7.4 Musculoskeletal Pain and Osteoarthritis

Several studies found that proteolytic enzymes might be helpful for neck pain, osteoarthritis, and post-herpetic neuralgia (an aftereffect of shingles). Proteolytic enzymes may be useful in reducing pain associated with moderate-to-severe knee osteoarthritis.

In one review study, researchers found that bromelain effectively reduced inflammation and stiffness in individuals with osteoarthritis. A study referenced in Mayo Clinic Proceedings compared oral enzyme combinations versus diclofenac: a double-blind prospective randomized study in knee osteoarthritis found the enzyme combination comparable to the NSAID, though the study has limitations including its relatively small sample size.

Proteolytic enzyme supplementation has also been shown to ease low back pain associated with lumbar spine osteoarthritis. Several studies suggest that proteolytic enzymes can reduce several types of pain. One double-blind study reported that proteolytic enzyme supplementation containing rutin resulted in a modest reduction in chronic neck and shoulder pain.

Evidence strength: Proteolytic enzymes can also be absorbed into the body whole and may help reduce inflammation and pain; however, the evidence is inconsistent. Several studies found that proteolytic enzymes might be helpful for neck pain, osteoarthritis, and post-herpetic neuralgia. However, these studies have significant limitations, like omitting a placebo group, and they do not provide substantially reliable information. Overall, this area shows promise but requires larger, better-controlled RCTs.

7.5 Sports Injuries and Exercise Recovery

Supplementing with proteolytic enzymes appears to be a particularly effective way to ease delayed-onset muscle soreness (DOMS), often experienced after a tough workout. In one clinical trial, 20 runners began taking a proteolytic enzyme supplement or a placebo, starting one day before participating in a downhill run and continuing for two days after the run. Individuals taking the supplement experienced significantly less DOMS compared to those taking the placebo. They also had less stiffness and better mobility after the run.

A study of 20 healthy men aged 18 to 29 years showed that protease supplements hasten the recovery of contractile capabilities and attenuate perceived increases in pain after downhill running. However, a double-blind randomized controlled trial with 40 participants showed no difference between bromelain and placebo in treating delayed-onset muscle soreness. A subsequent double-blind trial of 50 individuals with soft-tissue ankle injuries showed, on average, no significant difference in swelling, bruising, and function in the group given oral proteolytic enzymes vs enteric-coated lactose tablets.

Evidence strength: Currently, evidence of OTC enzymes improving muscle soreness in athletes is insufficient. Positive signals from some small trials are not consistent, and several better-designed RCTs have found no benefit. This remains an area of ongoing investigation.

7.6 Herpes Zoster (Shingles)

A double-blind multicenter trial of immunocompetent patients with herpes zoster showed the effectiveness of OTC enzymes in decreasing acute pain after oral ingestion. Earlier German-language clinical studies (referenced in systematic reviews) found enzyme therapy comparable to antiviral medication for certain zoster-associated pain parameters, though the quality and translation of these studies limits strong conclusions.

7.7 Oncology-Adjacent Evidence

Systemic enzyme therapy was recently subjected to experimental investigations and to rigorous clinical studies in cancer patients. The designs of the relevant clinical cohort studies followed the guidelines of Good Epidemiological Practice and represent level IIB in evidence-based medicine. Scientifically sound experimental in vitro and in vivo investigations document promising immunological, anti-inflammatory, anti-infectious, and antitumor/antimetastatic activities of proteolytic enzyme mixtures (containing trypsin, chymotrypsin, and papain) or bromelain.

Many OTC enzyme studies related to cancer focus on decreasing the complications of therapy, not on the effects on the disease process itself. Proteolytic enzymes have not been shown to prevent or treat cancer. Lab studies suggest that PEs can affect the growth of cancer cells. Although PEs were previously reported to benefit patients with cancer, more recent studies do not support such claims.

Evidence strength: Preclinical data are promising, but human evidence is weak and conflicting. Data from clinical studies are conflicting for cancer and treatment-related symptoms. The area requires well-designed, adequately powered RCTs before clinical conclusions can be drawn.

7.8 Immune Modulation

Under physiological conditions, the activity of peptidases is tightly regulated by a variety of factors. Dysregulation of peptidase activity is associated with a number of pathological processes. Proteolytic enzymes are essential for many important processes in the body, including cell division, blood clotting, immunity, and protein recycling.

The DPP-IV enzyme in particular has well-characterized immune-modulatory roles: DPP-IV inhibition may be useful for modulation of the immune response, based upon studies implicating the DPP-IV enzyme in T cell activation and in chemokine processing. DPP-IV has been shown to be identical to CD26, a cell surface marker for activated immune cells. The expression of CD26 is regulated by the differentiation and activation status of immune cells. These findings, however, primarily pertain to pharmaceutical-grade DPP-IV inhibitors (gliptins), not to supplemental forms of the enzyme.

7.9 Digestive Inflammation and Inflammatory Bowel Disease

Dysregulation of the proteolytic balance is often associated with diseases. Serine proteases and matrix metalloproteases are involved in a multitude of biological processes and notably in the inflammatory response. Within the framework of digestive inflammation, several studies have stressed the role of serine proteases and matrix metalloproteases as key actors in its pathogenesis. However, these findings pertain to endogenous enzyme dysregulation rather than demonstrating benefit from supplemental peptidase administration. Human clinical evidence for peptidase supplementation in IBD specifically remains very preliminary.

8. Body Systems and Health Areas

• Gastrointestinal system: Luminal protein digestion support; potential gluten/casein degradation; digestive symptom relief in malabsorption states.
• Musculoskeletal system: Anti-inflammatory and anti-edemic effects in joints, muscles, and post-surgical tissue; osteoarthritis symptom management.
• Immune system: Immunomodulatory properties via degradation of immune complexes; DPP-IV/CD26 signaling; T-cell activity modulation.
• Cardiovascular system: Fibrinolytic properties, particularly relevant to serratiopeptidase and nattokinase; antiplatelet effects observed with bromelain in laboratory settings.
• Dermatological and wound healing: Enzymatic débridement of necrotic tissue; acceleration of wound healing post-surgery and in burn management.
• Endocrine/metabolic system: DPP-IV's role in incretin regulation and glucose homeostasis (relevant primarily to pharmaceutical inhibitors, with emerging nutraceutical research).
• Neurological: Post-herpetic neuralgia; some preliminary evidence on gluten/casein-derived exorphin peptides and autism spectrum disorder behavioral correlates (limited and preliminary).

9. Dosage Forms and Doses Reported in Studies

Because "peptidase" encompasses multiple distinct enzymes, dosages differ substantially by enzyme type, formulation, and intended application. The following are doses as specifically reported in clinical studies and systematic sources:

• Serratiopeptidase: Serratiopeptidase 10 mg is equal to 20,000 units of enzyme activity. In clinical anti-inflammatory studies, doses of 10–30 mg have been used, typically in enteric-coated tablets. In one randomized trial of dental surgery, serratiopeptidase 15 mg was given twice daily for five days.
• Bromelain (combined trypsin formulations): Tibrolin® — a fixed-dose combination of trypsin 48 mg, bromelain 90 mg, and rutoside 100 mg — was used in clinical wound-healing trials. In another RCT, Tibrolin® D (trypsin 48 mg, bromelain 90 mg, rutoside 100 mg, and diclofenac 50 mg) was administered as one tablet orally, thrice a day postoperatively for seven days.
• Animal model doses (not directly extrapolatable to humans): Chymotrypsin at 5, 18, and 36 mg/kg; trypsin at 1.44, 2.88, and 5.76 mg/kg; and serratiopeptidase at 0.45, 0.9, and 2.70 mg/kg were studied for dose-dependent anti-inflammatory effects in rats.
• Bromelain (standalone): A study found that a 5-milligram oral dose of bromelain accelerated healing in people recovering from cosmetic surgery.
• General supplement ranges: Serrapeptase is dosed around 10–60 mg/day (often listed in units; approximately 20,000 units ≈ 10 mg) and should be enteric-coated and taken on an empty stomach.

10. Safety Considerations and Interactions

10.1 General Tolerability

Bromelain is considered a safe nutraceutical and has been used to treat various health problems. Most oral peptidase preparations are well-tolerated, with mild gastrointestinal disturbance being the most commonly reported adverse event in clinical literature. In one comparative study, one out of 20 patients that received serratiopeptidase showed mild gastrointestinal disturbance.

Side effects may be dose dependent or possibly due to a combination effect when used with other drugs. Detailed, scientifically designed controlled clinical studies need to be conducted to further examine the safety profile.

10.2 Drug Interactions

Anticoagulants and antiplatelets: If administered along with warfarin, clopidogrel, or aspirin, as well as with other natural remedies such as garlic, fish oil, and turmeric, there may be an increased risk of bleeding or bruising. Bromelain can enhance the effects of blood-thinning medications such as warfarin, aspirin, and clopidogrel, increasing the risk of bleeding. Additionally, combining bromelain with other anti-inflammatory drugs like NSAIDs may amplify their effects, potentially leading to gastrointestinal issues.

Bromelain may increase bleeding risk due to its antithrombotic effects observed in lab experiments, but clinical relevance is not known.

Drug interaction data limitations: There are no clinical studies reporting any drug interactions for serratiopeptidase. The only available information is from drug company monographs.

10.3 Allergy

Individuals with pineapple allergies should avoid bromelain, as it can trigger allergic reactions. Cross-reactivity between latex and papain has been documented in medical literature, and papain is a recognized occupational allergen in enzyme-processing industries.

10.4 Contraindications in Specific Populations

Patients should be excluded from peptidase therapy if they have a history of hypersensitivity to any of the ingredients of the formulation, hepatocellular insufficiency, hepatic failure, or active liver disease, severe renal impairment, a hereditary coagulation disorder, or are pregnant or breastfeeding.

10.5 Topical Papain Safety Alert

The U.S. Food and Drug Administration (FDA) in 2008 ordered a halt to the marketing of unapproved drug products that contain papain in a topical dosage form, because the drugs can produce harmful or near-fatal effects, with hypersensitivity resulting in anaphylactic reactions being the primary concern. The agency cited cases resulting in cardiovascular symptoms such as hypotension and tachycardia, some requiring emergency room visits and treatment with epinephrine. The FDA also asserted that the effectiveness of the products was not supported by scientifically sound studies.

10.6 Enzyme Variability and Standardization

A major limitation for the clinical use of bromelain is the variable extract composition, which results in heterogeneity of findings. The lack of universal standardization across commercial peptidase preparations makes it difficult to extrapolate doses and effects from research formulations to consumer products.

11. Summary of Evidence Strength

While proteolytic enzymes show promise for specific uses, further research is needed to establish their efficacy and safety comprehensively. The hierarchy of evidence by indication, as of the most recently available literature, may be summarized as:

• Best-supported: Pancreatic enzyme replacement in exocrine insufficiency (well-established, pharmaceutical-grade); post-surgical anti-edema and wound healing support (multiple RCTs, though often with combination products).
• Moderately supported: Osteoarthritis pain and stiffness reduction (several controlled studies, but methodological limitations); herpes zoster pain relief (older European clinical studies with limited modern replication).
• Preliminary/Insufficient: Sports recovery / delayed-onset muscle soreness (conflicting RCT data); gluten and casein digestion in celiac disease (promising mechanistic data, limited human RCTs); immune modulation (mainly in vitro and animal data).
• Not supported for clinical use: Prevention or treatment of cancer (no clinical proof; laboratory signals only).

References

• ScienceDirect Topics: Peptidase — an overview
• Rawlings et al. (2018). MEROPS database of proteolytic enzymes in 2017. Nucleic Acids Research
• Majer et al. (2022). Post-Proline Cleaving Enzymes: Classification, Structure, Molecular Properties, and Applications. PMC
• Rawlings et al. MEROPS: the peptidase database. PMC
• Barrett et al. The MEROPS database as a protease information system. PubMed
• PMC Editorial: Peptidases as a therapeutic target in anti-cancer management
• Rachael Saylor et al. (2014). Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know. Mayo Clinic Proceedings
• Beuth J. (2008). Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction? PubMed
• Bhagat S et al. (2013). Serratiopeptidase: A systematic review of the existing evidence. International Journal of Surgery
• Jadhav et al. (2020). Serratiopeptidase: Insights into the therapeutic applications. Biomedicine & Pharmacotherapy
• Mazzone A et al. Effect of Some Clinically Used Proteolytic Enzymes on Inflammation in Rats. PMC
• Locci C et al. (2024). Exploring the Therapeutic Potential of Bromelain: Applications, Benefits, and Mechanisms. PMC
• Locci C et al. (2024). Current Uses of Bromelain in Children: A Narrative Review. PMC
• Rolland-Fourcade et al. (2021). Digestive Inflammation: Role of Proteolytic Dysregulation. PMC
• Safety and Effectiveness of a Fixed-Dose Combination of Trypsin, Bromelain, and Rutoside in Wound Management: A Randomized Clinical Trial. PMC
• Safety and Efficacy of a Fixed-Dose Combination of Trypsin, Bromelain, Rutoside, and Diclofenac in Wound Management. PMC
• Chandra RB et al. (2023). Comparison of Efficacy of Combination of Bromelain, Rutocide, and Trypsin With Serratiopeptidase on Postoperative Sequelae. PMC / Cureus
• Scientific Reports (2025). Systemic enzyme therapy for postoperative inflammation and wound healing after orthopedic surgery: a randomized, placebo and active controlled clinical study
• Mora-Ortiz et al. (2022). In Vivo and In Vitro Comparison of the DPP-IV Inhibitory Potential of Food Proteins. PMC
• Memorial Sloan Kettering Cancer Center: Proteolytic Enzymes — About Herbs, Botanicals & Other Products
• EBSCO Research Starters: Proteolytic Enzymes as a Therapeutic Supplement
• IntechOpen (2024). Formulation of Milk Protein-Derived Dipeptidyl Peptidase-IV Inhibitory Peptides Rich Dietary Supplement
• Commercial Gluten Digestive Enzymes Have Lower Proteolytic Activity than Pure DPP-IV Enzyme. ScholarSphere/Penn State
• ScienceDirect Topics: Papain — an overview